Okami Medical Secures $45 Million in Funding for Expansion and Clinical Trials
Okami Medical, based in Aliso Viejo, has recently announced the successful closure of an oversubscribed financing round that raised $45 million. This financial injection is strategically aimed at accelerating the company’s commercial expansion and advancing its ongoing clinical trials. The investment underscores the growing interest in innovative medical technologies and the potential of Okami’s groundbreaking products within the healthcare sector.
The financing round was primarily led by Glide Healthcare, a new investor that recognized the potential of Okami’s technologies. Existing investors, including Vensana Capital and U.S. Venture Partners, also participated, highlighting ongoing confidence in Okami’s prospects. This level of engagement from multiple investors signals a robust market interest in what Okami Medical is achieving and the promising future ahead for the company.
Drew Hykes, the newly appointed Chief Executive Officer of Okami Medical, expressed his excitement about joining the team, noting the impressive clinical performance and versatility of their flagship product, the LOBO vascular occluder. The device has shown substantial effectiveness across a diverse range of anatomies, making it a crucial tool in various medical applications. Hykes’s background and vision will be instrumental as the company navigates this expansion and aims for a successful trajectory.
In addition to the funding, the transition also includes personnel changes at Okami Medical. With the new investment from Glide Healthcare, executives Geoff Pardo and Susana Amorim have stepped onto Okami’s board of directors. Their expertise will likely provide invaluable guidance as the company embarks on this next chapter of growth. The addition of new board members often brings fresh perspectives that can spur innovative strategies and solutions.
Okami Medical’s commitment to advancing clinical trials is a testament to its dedication to developing safe, effective, and state-of-the-art medical technologies. The funding will enable the company to enhance its research efforts, driving the development of new products that can meet unfulfilled medical needs. Through rigorous clinical testing, Okami aims to solidify its position in the competitive medical device market.
As Okami Medical continues its journey, the implications of this funding extend beyond the company itself. Such investment in healthcare innovation signals a strong optimism about the future of medical technologies and the potential for improvements in patient care. With Okami at the forefront, the landscape of vascular occlusion devices is primed for transformation, making it a space to watch in the coming years.
This article is based on reporting from www.ocbj.com.
The original version of the story can be found on their website.
Original Source:
www.ocbj.com
Image Credit: www.ocbj.com ·
View image